GlassScriptPhysician profile
Tanya E Rowell
NPI 1841661329
$1,995.39
in general payments reported to CMS, 2019-2025
11 companies · $733 in 2025
The $733 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $383 · 2022: $130 · 2023: $222 · 2024: $528 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.02 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $646.17 | 2021-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $373.74 | 2021-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $329.82 | 2021-2025 | Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $245.71 | 2025 | Caplyta |
| Abbvie INC. | $151.39 | 2021-2023 | |
| Currax Pharmaceuticals LLC | $84.59 | 2023 | Onzetra Xsail, Contrave, Nexletol |
| Corium, LLC | $76.69 | 2024-2025 | Azstarys |
| Glaxosmithkline, LLC. | $35.20 | 2025 | Bexsero |
| Dexcom, INC. | $24.46 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $14.47 | 2025 | |
| Janssen Pharmaceuticals, INC | $13.15 | 2023 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Rowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.